IN THE MATTER OF AN ARBITRATION UNDER CHAPTER ELEVEN OF THE NORTH AMERICAN FREE TRADE AGREEMENT AND THE UNCITRAL ARBITRATION RULES (1976) BETWEEN: ELI LILLY AND COMPANY Claimant/Investor AND: GOVERNMENT OF CANADA Respondent/Party (Case No. UNCT/14/2) AMICUS CURIAE SUBMISSIONS BY THE CANADIAN GENERIC PHARMACEUTICAL ASSOCIATION Jonathan Stainsby Daniel Hynes Aitken Klee LLP 181 Bay Street, Suite 3350 Toronto, Ontario Canada, M5J 2T3 Tel: (647) 317-6868 Fax: (613) 695-5854 E-mail:
[email protected] E-mail:
[email protected] Amicus Curiae Submissions CGPA Eli Lilly and Company, Claimant/Investor and Canada, Respondent/Party (Case No. UNCT/14/2) AMICUS CURIAE SUBMISSIONS of the CANADIAN GENERIC PHARMACEUTICAL ASSOCIATION 1. The Canadian Generic Pharmaceutical Association (‘CGPA’) appreciates the opportunity to provide these submissions in connection with the arbitration between Eli Lilly and Company (‘Lilly’) and Canada. The CGPA’s motivation and basis for seeking to file an amicus brief on this arbitration, as well as the significant public interest in the outcome of this arbitration, are set out in the CGPA’s application for leave to file these submissions and will not be re-iterated here. Preliminary Issue 2. Investor-state arbitrations under NAFTA are not intended as ‘blanket protection’ for investors against the mere disappointment arising from rejected complaints before national courts or from dealing with national authorities.1 The Tribunal should be mindful that Lilly’s arguments, as they relate to Canadian patent law, have been fully canvassed and adjudicated by Canadian Courts, the very courts charged with interpreting and applying domestic Canadian patent law.